Regenxbio Inc (NASDAQ:RGNX) crossed MACD Bullish signal line on Friday, June 26, 2020

0
62

Bullish Regenxbio Inc NASDAQ:RGNX Grade : F stock signal line crossed on Friday, June 26, 2020. on Thursday 11th June’s trading session, with a change of 8.86% per share while daily volume of 574,600 changed hands which is surge of 1.4%

Regenxbio Inc NASDAQ:RGNX Grade : F stock RGNX closed up 8.86 percent on Thursday, June 25, 2020, on 1.4 times normal volume.

Earning Regenxbio Inc NASDAQ:RGNX

Regenxbio last announced its earnings results on May 7th, 2020. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by $0.21. The company earned $17.60 million during the quarter, compared to analysts’ expectations of $17.99 million. Its quarterly revenue was up 1855.6% compared to the same quarter last year. Regenxbio has generated ($3.26) earnings per share over the last year. Regenxbio has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 5th, 2020 based off prior year’s report dates.

About Regenxbio Inc NASDAQ:RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company’s lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Grade : F